Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
June 14, 2004
- SEMIANNUAL SALES
June 14, 2004
- New Drugs Prolong Longevity by 3 Weeks Per Year: Dr Lichtenberg
June 14, 2004
- BULLETIN
June 14, 2004
- MR-Kun Service Could Begin This Autumn in the US: So-net M3
June 14, 2004
- Hakuhodo to Support Drug Companies to Educate Patients
June 14, 2004
- BUSINESS NEWS IN BRIEF
June 14, 2004
- New NHI Drug Pricing Needs Further Reform: Dr Hayakawa
June 14, 2004
- Korosho Explains Japan-EU Mutual GMP Recognition System
June 14, 2004
- REGULATORY NEWS IN BRIEF
June 14, 2004
- Sumitomo Pharmaceuticals: Sales Fall 1% to \136.9 Bil.
June 7, 2004
- Semiannual Business Results
June 7, 2004
- JPMA to Help Industry Contribute to Global Healthcare: Dr Aoki
June 7, 2004
- Towa Yakuhin: Sales of \23.1 Bil. Make It No.1 GE Maker
June 7, 2004
- Takara Bio Reports Antithrombotic Action of Fucoidan Oligosaccharides
June 7, 2004
- Annual Business Results
June 7, 2004
- Taiyo: Contract Mfg. Boosts Sales to \22.8 Bil.
June 7, 2004
- BULLETIN
June 7, 2004
- Kuraya Sanseido: Sales Increase 0.7%, Profits Up 57.1%
June 7, 2004
- Sawai: GE Promotion Helps Boost Sales, Profits
June 7, 2004
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…